Silence Therapeutics PLC
OTC:SLNCF

Watchlist Manager
Silence Therapeutics PLC Logo
Silence Therapeutics PLC
OTC:SLNCF
Watchlist
Price: 2 USD Market Closed
Market Cap: 280.8m USD

Relative Value

There is not enough data to reliably calculate the relative value of SLNCF.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SLNCF Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
146.6
Median 5Y
268.1
Industry
8
vs History
vs Industry
Median 3Y
-9.1
Median 5Y
-16.6
Industry
23.5
vs History
vs Industry
Median 3Y
15.9
Median 5Y
29.1
Industry
21.9
vs History
vs Industry
Median 3Y
16.4
Median 5Y
30
Industry
24.3
vs History
vs Industry
Median 3Y
7.4
Median 5Y
13.5
Industry
3.2
vs History
vs Industry
Median 3Y
110.4
Median 5Y
231.9
Industry
8.1
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
vs History
vs Industry
Median 3Y
-5.7
Median 5Y
-12
Industry
5.9
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-11.8
Industry
6.2
vs History
vs Industry
Median 3Y
12
Median 5Y
25.2
Industry
7.7
vs History
vs Industry
Median 3Y
12.4
Median 5Y
26
Industry
6.3
vs History
vs Industry
Median 3Y
3.1
Median 5Y
6.5
Industry
5.6

Multiples Across Competitors

SLNCF Competitors Multiples
Silence Therapeutics PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Silence Therapeutics PLC
OTC:SLNCF
280.8m USD 150 -9.3 -5.9 -5.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 766 261.7 -160 486 -194 881.2 -192 657.4
US
Abbvie Inc
NYSE:ABBV
405.3B USD 6.8 172.6 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
176.3B USD 4.9 25.2 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
151B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD 9.8 31.2 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 086.4 -532.4 -579.7 -564.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.7B USD 5.7 17.9 17 19.3
AU
CSL Ltd
ASX:CSL
83.3B AUD 3.6 18.6 12.5 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD 16.4 1 210.6 163.2 198
NL
argenx SE
XBRU:ARGX
44.3B EUR 14.4 33.9 58.5 60.1
P/E Multiple
Earnings Growth PEG
UK
Silence Therapeutics PLC
OTC:SLNCF
Average P/E: 191.1
Negative Multiple: -9.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 486 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
10%
1.8
AU
CSL Ltd
ASX:CSL
18.6
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 210.6
N/A N/A
NL
argenx SE
XBRU:ARGX
33.9
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Silence Therapeutics PLC
OTC:SLNCF
Average EV/EBITDA: 40.2
Negative Multiple: -5.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 881.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
11%
1.5
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
163.2
N/A N/A
NL
argenx SE
XBRU:ARGX
58.5
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Silence Therapeutics PLC
OTC:SLNCF
Average EV/EBIT: 46.4
Negative Multiple: -5.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 657.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.3
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
198
N/A N/A
NL
argenx SE
XBRU:ARGX
60.1
N/A N/A